Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours

Obiettivo

UTUC is a non-systemically treatable cancer that forms in the renal pelvis or ureter, frequently recurring due to ineffective systemic chemotherapy. With 5-10% of urothelial cancers being UTUC, current surgical treatment solutions pose significant hardships on patients and decrease their quality of life. Our proprietary solution, Padeliporfin-VTP therapy, offers a minimally invasive and effective alternative to surgery. This therapy delivers an inactive photosensitizer drug that is precisely activated in the tumour micro-environment by non-thermal laser light, immediately impeding the tumour's blood supply, leading to cell death with minimal effect on healthy tissues. This treatment not only effectively eliminates tumours, but also preserves organ functionality for potential future treatments. This project is led by a team of accomplished professionals in the pharmaceutical and biopharma industry, which solidifies our capability in innovating best-in-class therapeutic solutions. Utilising this funding, we aim to achieve regulatory approval (TRL9), scale production, and achieve market penetration in a market projected to reach €4.39B by 2032.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC-ACC - HORIZON EIC Accelerator

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2024-ACCELERATOR-02

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

IMPACT BIOTECH LTD
Contributo netto dell'UE
€ 2 498 730,50
Indirizzo
EINSTEIN ST. 18
7403620 NESS TZIONA
Israele
PMI
Sì
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
Nessun dato